發(fā)簡信
IP屬地：加州
一、前言 近年來，隨著干細(xì)胞治療、免疫細(xì)胞治療和基因編輯等基礎(chǔ)理論、技術(shù)手段和臨床醫(yī)療探索研究的不斷發(fā)展，細(xì)胞治療產(chǎn)品為一些嚴(yán)重及難治性疾病提供...
1.制定發(fā)布《細(xì)胞治療產(chǎn)品研究與評價技術(shù)指導(dǎo)原則》的背景是什么？ 細(xì)胞治療技術(shù)是目前國際醫(yī)學(xué)前沿重點發(fā)展領(lǐng)域，它給一些人類疑難疾病的治療提供了新...
Emerging immuno-oncology player Tessa Therapeutics has raised $80 millio...
WALTHAM, Mass.,Dec. 20, 2017/PRNewswire/ -- Juno Therapeutics (NASDAQ:JU...
The blood-brain barrier disruption appears to be “a unique mechanism wit...
PHILADELPHIA,Nov. 17, 2017/PRNewswire/ -- WuXi AppTec (WuXi), a leading ...
Seattle Children’s has opened the first chimeric antigen receptor (CAR) ...
The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab...
The FDA has granted Bluebird bb2121 a breakthrough therapy designation f...